



# ADNI

ALZHEIMER'S DISEASE  
NEUROIMAGING INITIATIVE

**ADNI Clinical Core**

Ron Petersen

April 24, 2017

# The ADNI Study

- ▶ Informing the design of therapeutic trials by looking at clinical, imaging, biomarker, and genetic characteristics across NL, MCI, and AD cohorts

	<b>ADNI1</b>	<b>ADNIGO</b>	<b>ADNI2</b>	<b>ADNI3*</b>
Duration	2004-2009	2009-2011	2011-2016	2016-2021
Sample Size	800	200	1180	1070-2000
Cohorts	NL, MCI, AD	EMCI	NL, SMC, EMCI, LMCI, AD	NL, MCI, AD

\*ADNI3 started September 2016

## ADNI2 Enrollment

- ▶ Total at initial entry (includes ADNI1 & GO rollovers): 1183
- ▶ Enrolled minus reported withdrawal: 828 (reported in 2016 ADNI SCM)
- ▶ Enrolled minus reported withdrawals: 789 (current)

**Need to ensure all ADNI2 data is entered!  
ADNI3 data cleaning efforts to commence  
Fall 2017**

# ADNI2 Clinical Summary

	CN n=314	SMC n=107	EMCI n=300	LMCI n=312	AD n=150	Combined n=1183	P
<b>Age (yrs)</b>	74.1 (5.8)	72.2 (5.6)	71.2 (7.4)	73.1 (7.4)	74.7 (8.2)	73.0 (7.0)	<0.001
<b>Female</b>	158 (50%)	62 (58%)	133 (44%)	127 (41%)	62 (41%)	542 (46%)	0.008
<b>Education</b>	16.5 (2.6)	16.8 (2.5)	16.0 (2.7)	16.1 (2.8)	15.8 (2.7)	16.2 (2.7)	0.007
<b>CDR-SB</b>	0.0 (0.1)	0.07 (0.2)	1.3 (0.8)	1.6 (1.0)	4.5 (1.7)	1.3 (1.7)	<0.001
<b>ADAS 13</b>	5.8 (3.0)	5.6 (2.7)	7.9 (3.5)	11.1 (4.6)	20.8 (7.1)	9.6 (6.4)	<0.001
<b>MMSE</b>	29.0 (1.2)	29.0 (1.2)	28.4 (1.8)	27.8 (1.8)	23.1 (2.1)	27.7 (2.4)	<0.001

# Please encourage participation in ADNI3!

- ▶ We need 700-800 rollover participants (of the total, N = 1070-2000)
- ▶ Cognitively normal cohort:
  - ▶ 295-330 rollover
  - ▶ 135-500 new
- ▶ MCI cohort:
  - ▶ 275-320 rollover
  - ▶ 150-515 new
- ▶ AD cohort:
  - ▶ 130-150 rollover
  - ▶ 85-185 new

In total ~790  
rollovers have  
been promised


# All Rollovers expected in the 1st year of ADNI3 - by September 2017

- ▶ 19 of the 59 sites approved ☹️
- ▶ Some sites have up to 30 rollover participants
- ▶ Plus activity for newly enrolled; screening open for two years – September 2018

If you are not approved yet, you will have a busy summer

# New recruitment tools for ADNI3

- ▶ Brain Health Registry
- ▶ Other registries
- ▶ ATRI Recruitment Core
  - ▶ Recruitment website: ADNI3.org
    - ▶ Call 800 number
    - ▶ Eligibility screener
    - ▶ Site location finder



1-888-223-6495 [JOIN OUR STUDY >](#)

 ADNI

[ALZHEIMER'S DISEASE](#) [OUR STUDY](#) [AM I ELIGIBLE? ▾](#) [ABOUT CLINICAL RESEARCH](#)

[FIND A LOCATION](#)

Did you know you can help make Alzheimer's history?

The Alzheimer's Disease Neuroimaging Initiative (ADNI) Study

[JOIN OUR STUDY >](#)

The screenshot shows a website header with a dark grey bar containing a phone number and a 'JOIN OUR STUDY >' button. Below this is the ADNI logo and a navigation menu with links for 'ALZHEIMER'S DISEASE', 'OUR STUDY', 'AM I ELIGIBLE? ▾', and 'ABOUT CLINICAL RESEARCH'. A 'FIND A LOCATION' link is also present. The main content area features a large image of an elderly couple riding a bicycle together, with a text overlay asking 'Did you know you can help make Alzheimer's history?' and providing information about the ADNI study, including a 'JOIN OUR STUDY >' button.

# Newly Added Assessments / Procedures & Corresponding eCRF

Newly Added Assessment / Procedure	Corresponding eCRF	Visits assessed
MINT (Multi-lingual Naming Test) <i>replacing Boston Naming</i>	Neuropsychometric Battery	Each in-clinic visit
Financial Capacity Instrument (FCI)	Financial Capacity Instrument (FCI)	Each in-clinic visit
Cogstate Brief Battery (CBB)	Cogstate Brief Battery	Each in-clinic visit* and remotely every 4 months
Tau PET imaging	Tau PET Scan Information	At beginning and end, +2 more AMY +/-, AD at every in-clinic visit
Florbetaben (FBB) PET imaging	Amyloid PET Scan Information	At baseline/Initial and then every other year for select new participants